Table of Content

Chapter 1:INTRODUCTION

1.1.Report description
1.2.Key benefits for stakeholders
1.3.Key market segments

1.3.1.List of key players profiled in the report

1.4.Research methodology

1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models

Chapter 2:EXECUTIVE SUMMARY

2.1.Key findings of the study

2.1.1.CXO perspective

Chapter 3:MARKET OVERVIEW

3.1.Market definition and scope
3.2.Key findings

3.2.1.Top investment pockets

3.3.Porter’s five forces analysis

3.3.1.Bargaining power of buyers
3.3.2.Bargaining power of suppliers
3.3.3.Thereat of new entrants
3.3.4.Threat of substitutes
3.3.5.Intensity of competitive rivalry
3.3.6.Market share analysis, 2018

3.4.Market dynamics

3.4.1.Drivers

3.4.1.1.Increase in outbreaks of meningococcal disease
3.4.1.2.Surge in immunization programs across the globe
3.4.1.3.Increase in research and development for vaccine technology

3.4.2.Restraint

3.4.2.1.Longer timelines required for vaccine production
3.4.2.2.High costs associated with the development of vaccines

3.4.3.Opportunities

3.4.3.1.Growth opportunities in the emerging markets
3.4.3.2.Increase in healthcare spending
3.4.3.3.Increase in research and development for meningococcal vaccines

3.4.4.Impact analysis

Chapter 4:MENINGOCOCCAL VACCINE MARKET, BY VACCINE SEROTYPE

4.1.Overview

4.1.1.Market size and forecast

4.2.MenACYW Vaccine

4.2.1.Key market trends, growth factors, and opportunities
4.2.2.Market size and forecast, by region
4.2.3.Market analysis, by country

4.3.MenB/BC Vaccine

4.3.1.Key market trends, growth factors, and opportunities
4.3.2.Market size and forecast, by region
4.3.3.Market analysis, by country

4.4.MenC Vaccine

4.4.1.Key market trends, growth factors, and opportunities
4.4.2.Market size and forecast, by region
4.4.3.Market analysis, by country

4.5.MenA Vaccine

4.5.1.Key market trends, growth factors, and opportunities
4.5.2.Market size and forecast, by region
4.5.3.Market analysis, by country

4.6.MenAC Vaccine

4.6.1.Key market trends, growth factors, and opportunities
4.6.2.Market size and forecast, by region
4.6.3.Market analysis, by country

Chapter 5:MENINGOCOCCAL VACCINE MARKET, BY VACCINE TYPE

5.1.Overview

5.1.1.Market size and forecast

5.2.Conjugate Meningococcal Vaccines

5.2.1.Market size and forecast, by region
5.2.2.Market analysis, by country

5.3.Polysaccharide Vaccine

5.3.1.Market size and forecast, by region
5.3.2.Market analysis, by country

5.4.Subcapsular Vaccines

5.4.1.Market size and forecast, by region
5.4.2.Market analysis, by country

Chapter 6:MENINGOCOCCAL VACCINE MARKET, BY END USER

6.1.Overview

6.1.1.Market size and forecast

6.2.Pediatrics

6.2.1.Market size and forecast
6.2.2.Market analysis, by country

6.3.Adults

6.3.1.Market size and forecast
6.3.2.Market analysis, by country

6.4.Traveler

6.4.1.Market size and forecast
6.4.2.Market analysis, by country

Chapter 7:MENINGOCOCCAL VACCINE MARKET BY REGION

7.1.Overview

7.1.1.Market size and forecast

7.2.North America

7.2.1.Key market trends, growth factors, and opportunities
7.2.2.Market size and forecast, by country

7.2.2.1.U.S.

7.2.2.1.1.U.S. meningococcal vaccine market, by vaccine serotype
7.2.2.1.2.U.S. meningococcal vaccine market, by vaccine type
7.2.2.1.3.U.S. meningococcal vaccine market, by end user

7.2.2.2.Canada

7.2.2.2.1.Canada meningococcal vaccine market, by vaccine serotype
7.2.2.2.2.Canada meningococcal vaccine market, by vaccine type
7.2.2.2.3.Canada meningococcal vaccine market, by end user

7.2.2.3.Mexico

7.2.2.3.1.Mexico meningococcal vaccine market, by vaccine serotype
7.2.2.3.2.Mexico meningococcal vaccine market, by vaccine type
7.2.2.3.3.Mexico meningococcal vaccine market, by end user

7.2.3.North America meningococcal vaccine market, by vaccine serotype
7.2.4.North America meningococcal vaccine market, by vaccine type
7.2.5.North America meningococcal vaccine market, by end user

7.3.Europe

7.3.1.Key market trends, growth factors, and opportunities
7.3.2.Market size and forecast, by country

7.3.2.1.Germany

7.3.2.1.1.Germany Meningococcal vaccines market, by Serotype
7.3.2.1.2.Germany Meningococcal vaccines market, by Vaccine type
7.3.2.1.3.Germany Meningococcal vaccines market, by end user

7.3.2.2.France

7.3.2.2.1.France Meningococcal vaccines market, by Serotype
7.3.2.2.2.France Meningococcal vaccines market, by Vaccine type
7.3.2.2.3.France Meningococcal vaccines market, by end user

7.3.2.3.UK

7.3.2.3.1.UK Meningococcal vaccines market, by Serotype
7.3.2.3.2.UK Meningococcal vaccines market, by Vaccine type
7.3.2.3.3.UK Meningococcal vaccines market, by end user

7.3.2.4.The Netherlands

7.3.2.4.1.The Netherlands Meningococcal vaccines market, by Serotype
7.3.2.4.2.The Netherlands Meningococcal vaccines market, by Vaccine type
7.3.2.4.3.The Netherlands Meningococcal vaccines market, by end user

7.3.2.5.Spain

7.3.2.5.1.Spain Meningococcal vaccines market, by Serotype
7.3.2.5.2.Spain Meningococcal vaccines market, by Vaccine type
7.3.2.5.3.Spain Meningococcal vaccines market, by end user

7.3.2.6.Rest of Europe

7.3.2.6.1.Rest of Europe Meningococcal vaccines market, by Serotype
7.3.2.6.2.Rest of Europe Meningococcal vaccines market, by Vaccine type
7.3.2.6.3.Rest of Europe Meningococcal vaccines market, by end user

7.3.3.Europe Meningococcal vaccines market, by Serotype
7.3.4.Europe Meningococcal vaccines market, by Vaccine type
7.3.5.Europe Meningococcal vaccines market, by end user

7.4.Asia-Pacific

7.4.1.Key market trends, growth factors, and opportunities
7.4.2.Market size and forecast, by country

7.4.2.1.China

7.4.2.1.1.China meningococcal vaccine market, by vaccine serotype
7.4.2.1.2.China meningococcal vaccine market, by vaccine type
7.4.2.1.3.China meningococcal vaccine market, by end user

7.4.2.2.Australia

7.4.2.2.1.Australia meningococcal vaccine market, by vaccine serotype
7.4.2.2.2.Australia meningococcal vaccine market, by vaccine type
7.4.2.2.3.Australia meningococcal vaccine market, by end user

7.4.2.3.Rest of Asia-Pacific

7.4.2.3.1.Rest of Asia-Pacific meningococcal vaccine market, by vaccine serotype
7.4.2.3.2.Rest of Asia-Pacific meningococcal vaccine market, by vaccine type
7.4.2.3.3.Rest of Asia-Pacific meningococcal vaccine market, by end user

7.4.3.Asia-Pacific meningococcal vaccine market, by vaccine serotype
7.4.4.Asia-Pacific meningococcal vaccine market, by vaccine type
7.4.5.Asia-Pacific meningococcal vaccine market, by end user

7.5.LAMEA

7.5.1.Key market trends, growth factors, and opportunities
7.5.2.Market size and forecast, by country

7.5.2.1.Latin America

7.5.2.1.1.Latin America Meningococcal vaccines market, by Serotype
7.5.2.1.2.Latin America Meningococcal vaccines market, by Vaccine type
7.5.2.1.3.Latin America Meningococcal vaccines market, by end user

7.5.2.2.Middle East

7.5.2.2.1.Middle East Meningococcal vaccines market, by Serotype
7.5.2.2.2.Middle East Meningococcal vaccines market, by Vaccine type
7.5.2.2.3.Middle East Meningococcal vaccines market, by end user

7.5.2.3.Africa

7.5.2.3.1.Africa Meningococcal vaccines market, by Serotype
7.5.2.3.2.Africa meningococcal vaccines market, by vaccine type
7.5.2.3.3.Africa meningococcal vaccines market, by end user

7.5.3.LAMEA meningococcal vaccines market, by serotype
7.5.4.LAMEA meningococcal vaccines market, by vaccine type
7.5.5.LAMEA meningococcal vaccines market, by end user

Chapter 8:COMPANY PROFILES

8.1.Bio-Manguinhos

8.1.1.Company overview
8.1.2.Company snapshot
8.1.3.Operating business segments
8.1.4.Product portfolio

8.2.Bio-Med Pvt. Limited

8.2.1.Company overview
8.2.2.Company snapshot
8.2.3.Operating business segments
8.2.4.Product portfolio

8.3.Chongqing Zhifei Biological Products Co., Ltd.

8.3.1.Company overview
8.3.2.Company snapshot
8.3.3.Operating business segments
8.3.4.Product portfolio

8.4.GlaxoSmithKline Plc

8.4.1.Company overview
8.4.2.Company snapshot
8.4.3.Operating business segments
8.4.4.Product portfolio
8.4.5.Business performance
8.4.1.Key strategic moves and developments

8.5.Hualan Biological Engineering Inc.

8.5.1.Company overview
8.5.2.Company snapshot
8.5.3.Operating business segments
8.5.4.Product portfolio

8.6.Incepta Pharmaceuticals Ltd.

8.6.1.Company overview
8.6.2.Company snapshot
8.6.3.Operating business segments
8.6.4.Product portfolio

8.7.PFIZER INC.

8.7.1.Company overview
8.7.2.Company snapshot
8.7.3.Operating business segments
8.7.4.Product portfolio
8.7.5.Business performance

8.8.SANOFI S.A.

8.8.1.Company overview
8.8.2.Company snapshot
8.8.3.Operating business segments
8.8.4.Product portfolio
8.8.5.Business performance

8.9.SERUM INSTITUTE OF INDIA PVT. LTD

8.9.1.Company overview
8.9.2.Company snapshot
8.9.3.Operating business segments
8.9.4.Product portfolio

8.10.Walvax Biotechnology Co., Ltd.

8.10.1.Company overview
8.10.2.Company snapshot
8.10.3.Operating business segments
8.10.4.Product portfolio



List of Figures



FIGURE 01.MENINGOCOCCAL VACCINE MARKET SEGMENTATION
FIGURE 02.TOP INVESTMENT POCKETS IN THE GLOBAL MENINGOCOCCAL VACCINE MARKET, 2018
FIGURE 03.MODERATE BARGAINING POWER OF BUYERS
FIGURE 04.MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 05.MODERATE THREAT OF NEW ENTRANTS
FIGURE 06.HIGH COMPETITIVE RIVALRY
FIGURE 07.MARKET SHARE ANALYSIS, 2018
FIGURE 08.IMPACT ANALYSIS
FIGURE 09.COMPARATIVE ANALYSIS OF MENINGOCOCCAL VACCINE MARKET, BY COUNTRY, 2018 & 2026, BY VALUE
FIGURE 10.COMPARATIVE ANALYSIS OF MENINGOCOCCAL VACCINE MARKET FOR MENB MARKET, BY COUNTRY, 2018 & 2026, BY VALUE
FIGURE 11.COMPARATIVE ANALYSIS OF MENINGOCOCCAL VACCINE MARKET FOR MENC MARKET, BY COUNTRY, 2018 & 2026, BY VALUE
FIGURE 12.COMPARATIVE ANALYSIS OF MENINGOCOCCAL VACCINE MARKET FOR MENA VACCINE MARKET, BY COUNTRY, 2018 & 2026 BY VALUE
FIGURE 13.COMPARATIVE ANALYSIS OF MENINGOCOCCAL VACCINE MARKET FOR MENAC VACCINE MARKET, BY COUNTRY, 2018 & 2026 BY VALUE
FIGURE 14.COMPARATIVE ANALYSIS OF CONJUGATE MENINGOCOCCAL VACCINES MARKET, BY COUNTRY, 2018 & 2026 (%), BY VALUE
FIGURE 15.COMPARATIVE ANALYSIS OF POLYSACCHARIDE VACCINE MARKET, BY COUNTRY, 2018 & 2026 (%), BY VALUE
FIGURE 16.COMPARATIVE ANALYSIS OF SUBCAPSULAR MENINGOCOCCAL VACCINE, BY COUNTRY, 2018 & 2026 (%), BY VALUE
FIGURE 17.COMPARATIVE ANALYSIS OF MENINGOCOCCAL VACCINES MARKET FOR PEDIATRICS, 2018 & 2026, ($MILLION)
FIGURE 18.COMPARATIVE ANALYSIS OF MENINGOCOCCAL VACCINES MARKET FOR ADULTS, 2018 & 2026, ($MILLION)
FIGURE 19.COMPARATIVE ANALYSIS OF MENINGOCOCCAL VACCINES MARKET FOR TRAVELLERS, 2018 & 2026, ($MILLION)
FIGURE 20.GSK: NET SALES, 2017–2018 ($MILLION)
FIGURE 21.GSK REVENUE SHARE BY SEGMENTS, 2018 (%)
FIGURE 22.GSK: REVENUE SHARE BY REGIONS, 2018 (%)
FIGURE 23.NET SALES, 2016–2018 ($MILLION)
FIGURE 24.PFIZER: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 25.PFIZER: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 26.SANOFI: NET SALES, 2016–2018 ($MILLION)
FIGURE 27.SANOFI: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 28.SANOFI: REVENUE SHARE BY REGION, 2018 (%)


List of Tables



TABLE 01.GLOBAL MENINGOCOCCAL VACCINES MARKET, BY VACCINE SEROTYPE, 2018–2026 ($MILLION)
TABLE 02.MENACWY VACCINE MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 03.MENINGOCOCCAL VACCINE MARKET FOR MENB AND BC VACCINE MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 04.MENINGOCOCCAL VACCINE MARKET FOR MENC MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 05.MENINGOCOCCAL VACCINE MARKET FOR MENA VACCINE MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 06.MENINGOCOCCAL VACCINE MARKET FOR MENAC VACCINE MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 07.GLOBAL MENINGOCOCCAL VACCINE MARKET, BY VACCINE TYPE, 2018–2026 ($MILLION)
TABLE 08.COMPETITIVE CONJUGATE MENINGOCOCCAL VACCINES MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 09.POLYSACCHARIDE MENINGOCOCCAL VACCINES MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 10.SUBCAPSULAR MENINGOCOCCAL VACCINES MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 11.GLOBAL MENINGOCOCCAL VACCINES MARKET, BY END USER, 2018–2026 ($MILLION)
TABLE 12.MENINGOCOCCAL VACCINES MARKET FOR PEDIATRICS, BY REGION, 2018–2026 ($MILLION)
TABLE 13.MENINGOCOCCAL VACCINES MARKET FOR ADULTS, BY REGION, 2018–2026 ($MILLION)
TABLE 14.MENINGOCOCCAL VACCINES MARKET FOR TRAVELLERS, BY REGION, 2018–2026 ($MILLION)
TABLE 15.MENINGOCOCCAL VACCINE MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 16.NORTH AMERICA MENINGOCOCCAL VACCINE MARKET, BY COUNTRY, 2018–2026 ($MILLION)
TABLE 17.U.S. MENINGOCOCCAL VACCINE MARKET, BY VACCINE SEROTYPE, 2018–2026 ($MILLION)
TABLE 18.U.S. MENINGOCOCCAL VACCINE MARKET, BY VACCINE TYPE, 2018–2026 ($MILLION)
TABLE 19.U.S. MENINGOCOCCAL VACCINE MARKET, BY END USER, 2018–2026 ($MILLION)
TABLE 20.CANADA MENINGOCOCCAL VACCINE MARKET, BY SEROTYPE, 2018–2026 ($MILLION)
TABLE 21.CANADA MENINGOCOCCAL VACCINE MARKET, BY VACCINE TYPE, 2018–2026 ($MILLION)
TABLE 22.CANADA MENINGOCOCCAL VACCINE MARKET, BY END USER, 2018–2026 ($MILLION)
TABLE 23.MEXICO MENINGOCOCCAL VACCINE MARKET, BY VACCINE SEROTYPE, 2018–2026 ($MILLION)
TABLE 24.MEXICO MENINGOCOCCAL VACCINE MARKET, BY VACCINE TYPE, 2018–2026 ($MILLION)
TABLE 25.MEXICO MENINGOCOCCAL VACCINE MARKET, BY END USER, 2018–2026 ($MILLION)
TABLE 26.NORTH AMERICA MENINGOCOCCAL VACCINE MARKET, BY VACCINE SEROTYPE, 2018–2026 ($MILLION)
TABLE 27.NORTH AMERICA MENINGOCOCCAL VACCINE MARKET, BY VACCINE TYPE, 2018–2026 ($MILLION)
TABLE 28.NORTH AMERICA MENINGOCOCCAL VACCINE MARKET, BY END USER, 2018–2026 ($MILLION)
TABLE 29.EUROPE MENINGOCOCCAL VACCINES MARKET, BY COUNTRY, 2018–2026 ($MILLION)
TABLE 30.GERMANY MENINGOCOCCAL VACCINES MARKET, BY SEROTYPE, 2018–2026 ($MILLION)
TABLE 31.GERMANY MENINGOCOCCAL VACCINES MARKET, BY VACCINE TYPE, 2018–2026 ($MILLION)
TABLE 32.GERMANY MENINGOCOCCAL VACCINES MARKET, BY END USER, 2018–2026 ($MILLION)
TABLE 33.FRANCE MENINGOCOCCAL VACCINES MARKET, BY SEROTYPE, 2018–2026 ($MILLION)
TABLE 34.FRANCE MENINGOCOCCAL VACCINES MARKET, BY VACCINE TYPE, 2018–2026 ($MILLION)
TABLE 35.FRANCE MENINGOCOCCAL VACCINES MARKET, BY END USER, 2018–2026 ($MILLION)
TABLE 36.UK MENINGOCOCCAL VACCINES MARKET, BY SEROTYPE, 2018–2026 ($MILLION)
TABLE 37.UK MENINGOCOCCAL VACCINES MARKET, BY VACCINE TYPE, 2018–2026 ($MILLION)
TABLE 38.UK MENINGOCOCCAL VACCINES MARKET, BY END USER, 2018–2026 ($MILLION)
TABLE 39.THE NETHERLANDS MENINGOCOCCAL VACCINES MARKET, BY SEROTYPE, 2018–2026 ($MILLION)
TABLE 40.THE NETHERLANDS MENINGOCOCCAL VACCINES MARKET, BY VACCINE TYPE, 2018–2026 ($MILLION)
TABLE 41.THE NETHERLANDS MENINGOCOCCAL VACCINES MARKET, BY END USER, 2018–2026 ($MILLION)
TABLE 42.SPAIN MENINGOCOCCAL VACCINES MARKET, BY SEROTYPE, 2018–2026 ($MILLION)
TABLE 43.SPAIN MENINGOCOCCAL VACCINES MARKET, BY VACCINE TYPE, 2018–2026 ($MILLION)
TABLE 44.SPAIN MENINGOCOCCAL VACCINES MARKET, BY END USER, 2018–2026 ($MILLION)
TABLE 45.REST OF EUROPE MENINGOCOCCAL VACCINES MARKET, BY SEROTYPE, 2018–2026 ($MILLION)
TABLE 46.REST OF EUROPE MENINGOCOCCAL VACCINES MARKET, BY VACCINE TYPE, 2018–2026 ($MILLION)
TABLE 47.REST OF EUROPE MENINGOCOCCAL VACCINES MARKET, BY END USER, 2018–2026 ($MILLION)
TABLE 48.EUROPE MENINGOCOCCAL VACCINES MARKET, BY SEROTYPE, 2018–2026 ($MILLION)
TABLE 49.EUROPE MENINGOCOCCAL VACCINES MARKET, BY VACCINE TYPE, 2018–2026 ($MILLION)
TABLE 50.EUROPE MENINGOCOCCAL VACCINES MARKET, BY END USER, 2018–2026 ($MILLION)
TABLE 51.ASIA- PACIFIC MENINGOCOCCAL VACCINE MARKET, BY COUNTRY, 2018–2026 ($MILLION)
TABLE 52.CHINA MENINGOCOCCAL VACCINE MARKET, BY VACCINE SEROTYPE, 2018–2026 ($MILLION)
TABLE 53.CHINA MENINGOCOCCAL VACCINE MARKET, BY VACCINE TYPE, 2018–2026 ($MILLION)
TABLE 54.CHINA MENINGOCOCCAL VACCINE MARKET, BY END USER, 2018–2026 ($MILLION)
TABLE 55.AUSTRALIA MENINGOCOCCAL VACCINE MARKET, BY VACCINE SEROTYPE, 2018–2026 ($MILLION)
TABLE 56.AUSTRALIA MENINGOCOCCAL VACCINE MARKET, BY VACCINE TYPE, 2018–2026 ($MILLION)
TABLE 57.AUSTRALIA MENINGOCOCCAL VACCINE MARKET, BY END USER, 2018–2026 ($MILLION)
TABLE 58.REST OF ASIA-PACIFIC MENINGOCOCCAL VACCINE MARKET, BY VACCINE SEROTYPE, 2018–2026 ($MILLION)
TABLE 59.REST OF ASIA-PACIFIC MENINGOCOCCAL VACCINE MARKET, BY VACCINE TYPE, 2018–2026 ($MILLION)
TABLE 60.REST OF ASIA-PACIFIC MENINGOCOCCAL VACCINE MARKET, BY END USER, 2018–2026 ($MILLION)
TABLE 61.ASIA-PACIFIC MENINGOCOCCAL VACCINE MARKET, BY VACINE SEROTYPE, 2018–2026 ($MILLION)
TABLE 62.ASIA-PACIFIC MENINGOCOCCAL VACCINE MARKET, BY VACCINE TYPE, 2018–2026 ($MILLION)
TABLE 63.ASIA-PACIFIC MENINGOCOCCAL VACCINE MARKET, BY END USER, 2018–2026 ($MILLION)
TABLE 64.LAMEA MENINGOCOCCAL VACCINES MARKET, BY COUNTRY, 2018–2026 ($MILLION)
TABLE 65.LATIN AMERICA MENINGOCOCCAL VACCINES MARKET, BY SEROTYPE, 2018–2026 ($MILLION)
TABLE 66.LATIN AMERICA MENINGOCOCCAL VACCINES MARKET, BY VACCINE TYPE, 2018–2026 ($MILLION)
TABLE 67.LATIN AMERICA MENINGOCOCCAL VACCINES MARKET, BY END USER, 2018–2026 ($MILLION)
TABLE 68.MIDDLE EAST MENINGOCOCCAL VACCINES MARKET, BY SEROTYPE, 2018–2026 ($MILLION)
TABLE 69.MIDDLE EAST MENINGOCOCCAL VACCINES MARKET, BY VACCINE TYPE, 2018–2026 ($MILLION)
TABLE 70.MIDDLE EAST MENINGOCOCCAL VACCINES MARKET, BY END USER, 2018–2026 ($MILLION)
TABLE 71.AFRICA MENINGOCOCCAL VACCINES MARKET, BY SEROTYPE, 2018–2026 ($MILLION)
TABLE 72.AFRICA MENINGOCOCCAL VACCINES MARKET, BY VACCINE TYPE, 2018–2026 ($MILLION)
TABLE 73.AFRICA MENINGOCOCCAL VACCINES MARKET, BY END USER, 2018–2026 ($MILLION)
TABLE 74.LAMEA MENINGOCOCCAL VACCINES MARKET, BY SEROTYPE, 2018–2026 ($MILLION)
TABLE 75.LAMEA MENINGOCOCCAL VACCINES MARKET, BY VACCINE TYPE, 2018–2026 ($MILLION)
TABLE 76.LAMEA MENINGOCOCCAL VACCINES MARKET, BY END USER, 2018–2026 ($MILLION)
TABLE 77.BIO-MANGUINHOS: COMPANY SNAPSHOT
TABLE 78.BIO-MANGUINHOS: OPERATING SEGMENTS
TABLE 79.BIO-MANGUINHOS: PRODUCT PORTFOLIO
TABLE 80.BIO-MED: COMPANY SNAPSHOT
TABLE 81.BIO-MED: OPERATING SEGMENTS
TABLE 82.BIO-MED: PRODUCT PORTFOLIO
TABLE 83.ZHIFEI: COMPANY SNAPSHOT
TABLE 84.ZHIFEI: PRODUCT SEGMENTS
TABLE 85.ZHIFEI: PRODUCT PORTFOLIO
TABLE 86.GSK: COMPANY SNAPSHOT
TABLE 87.GSK: OPERATING SEGMENTS
TABLE 88.GSK: PRODUCT PORTFOLIO
TABLE 89.HUALAN BIO: COMPANY SNAPSHOT
TABLE 90.HUALAN BIO: OPERATING SEGMENTS
TABLE 91.HUALAN BIO: PRODUCT PORTFOLIO:
TABLE 92.INCEPTA: COMPANY SNAPSHOT
TABLE 93.INCEPTA: OPERATING SEGMENTS
TABLE 94.INCEPTA: PRODUCT PORTFOLIO
TABLE 95.PFIZER: COMPANY SNAPSHOT
TABLE 96.PFIZER: OPERATING SEGMENTS
TABLE 97.PFIZER: PRODUCT PORTFOLIO
TABLE 98.SANOFI: COMPANY SNAPSHOT
TABLE 99.SANOFI: OPERATING SEGMENTS
TABLE 100.SANOFI: PRODUCT PORTFOLIO:
TABLE 101.SERUM INSTITUTE.: COMPANY SNAPSHOT
TABLE 102.SERUM INSTITUTE: PRODUCT PORTFOLIO
TABLE 103.WALVAX: COMPANY SNAPSHOT
TABLE 104.WALVAX: OPERATING SEGMENTS
TABLE 105.WALVAX: PRODUCT PORTFOLIO